BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is one of the best low priced stocks to buy for the next 3 years.
On May 18, BioMarin’s Phase 3 ENERGY 3 trial of BMN 401 for children with ENPP1 deficiency met only one of its two co-primary endpoints
Treatment led to statistically significant increases in plasma inorganic pyrophosphate/PPi concentration through week 52 compared to conventional therapy. However, the drug failed to improve Radiographic Global Impression of Change/RGI-C scores, a critical measure of rickets severity. No positive trends were observed in secondary endpoints like growth Z-scores or Rickets Severity Scores, though the treatment was well-tolerated with no new safety signals. 15 States with the Best Healthcare in the US Management expressed disappointment that the increased PPi levels did not yield clinical benefits for the 27 pediatric participants.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is evaluating the data to determine its next steps and plans to present detailed results at an upcoming medical meeting. BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) develops and commercializes therapies for serious and life-threatening medical conditions and rare diseases. The company’s product pipeline includes Valoctocogene roxaparvovec, Vosoritide, and BMN 307.